Pimavanserin
| Use attributes for filter ! | |
| Molar mass | 427. 553 g/mol |
|---|---|
| Formula | C25H34FN3O2 |
| Other names | ACP-103; BVF-048 |
| Trade name | Nuplazid |
| ATC code | N05AX17 (WHO) |
| Metabolism | CYP3A4 |
| CYP3A5 | |
| CYP2J2 | |
| Music groups | Quetiapine |
| Clozapine | |
| Olanzapine | |
| Date of Reg. | |
| Date of Upd. | |
| ID | 2951735 |
About Pimavanserin
Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis and is also being researched for the treatment of Alzheimer's disease psychosis, schizophrenia, agitation, and major depressive disorder.